Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Targeting c‐MET by LY2801653 for treatment of cholangiocarcinoma

12 Jan 2016

Abstract excerpt

Palliative treatment options for human cholangiocarcinoma (CCC) are quite limited and new therapeutic strategies are of utmost need. c-MET has been shown to be deregulated in many cancers, but the role of c-MET in the carcinogenesis of CCC remains unclear. The main purpose of this study is to evaluate the expression and also to investigate the role of c-MET and its effective inhibition for the treatment of CCC....

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer, Hypoxia, and Metabolism
Share to Cholangiocarcinoma and Gallbladder Cancer Studies
Share to Liver physiology and pathology

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 26757360
DOI: 10.1002/mc.22449

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Targeting c‐MET by LY2801653 for treatment of cholangiocarcinomaPMID 26757360Read ↗

LY2801653 is an orally bioavailable multi-kinase inhibitor with potent activity against MET, MST1R, and other oncoproteins, and displays anti-tumor activities in mouse xenograft models.Semantic proximity Read ↗

Targeting the c-Met Signaling Pathway in CancerSemantic proximity Read ↗

Role of c-MET in upper aerodigestive malignancies--from biology to novel therapies.Semantic proximity Read ↗

CRIPTO promotes an aggressive tumour phenotype and resistance to treatment in hepatocellular carcinoma.Semantic proximity Read ↗

c-Met as a target for human cancer and characterization of inhibitors for therapeutic intervention.Semantic proximity Read ↗

[Mechanism of c-MET in Non-small Cell Lung Cancer and Its Treatment and Testing].Semantic proximity Read ↗

Targeting Angiogenesis in Biliary Tract Cancers: An Open Option.Semantic proximity Read ↗

Forty‐nine gastric cancer cell lines with integrative genomic profiling for development of c‐MET inhibitorSemantic proximity Read ↗

Targeting the c-MET signaling pathway for cancer therapySemantic proximity Read ↗

Function of the c-Met receptor tyrosine kinase in carcinogenesis and associated therapeutic opportunitiesSemantic proximity Read ↗

Yhhu3813 is a novel selective inhibitor of c-Met kinase that inhibits c-Met-dependent neoplastic phenotypes of human cancer cells.Semantic proximity Read ↗

c-Met is a potentially new therapeutic target for treatment of human melanoma.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.